Margaret C Fang1, Dongjie Fan2, Sue Hee Sung2, Daniel M Witt3, John R Schmelzer4, Marc S Williams5, Steven H Yale6, Christine Baumgartner7, Alan S Go8. 1. Division of Hospital Medicine, University of California, San Francisco. Electronic address: Margaret.Fang@ucsf.edu. 2. Division of Research, Kaiser Permanente Northern California, Oakland. 3. Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City. 4. Marshfield Clinic Research Institute, Wis. 5. Genomic Medicine Institute, Geisinger, Danville, Pa. 6. Department of Medicine, University of Central Florida College of Medicine, Orlando. 7. Division of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland. 8. Division of Research, Kaiser Permanente Northern California, Oakland; Departments of Epidemiology, Biostatistics and Medicine, University of California, San Francisco; Departments of Medicine, Health Research and Policy, Stanford University School of Medicine, Palo Alto, Calif.
Abstract
BACKGROUND: Few studies describe both inpatient and outpatient treatment and outcomes of patients with acute venous thromboembolism in the United States. METHODS: A multi-institutional cohort of patients diagnosed with confirmed pulmonary embolism or deep venous thrombosis during the years 2004 through 2010 was established from 4 large, US-based integrated health care delivery systems. Computerized databases were accessed and medical records reviewed to collect information on patient demographics, clinical risk factors, initial antithrombotic treatment, and vital status. Multivariable Cox regression models were used to estimate the risk of death at 90 days. RESULTS: The cohort comprised 5497 adults with acute venous thromboembolism. Pulmonary embolism was predominantly managed in the hospital setting (95.0%), while 54.5% of patients with lower extremity thrombosis were treated as outpatients. Anticoagulant treatment differed according to thromboembolism type: 2688 patients (92.8%) with pulmonary embolism and 1625 patients (86.9%) with lower extremity thrombosis were discharged on anticoagulants, compared with 286 patients (80.1%) with upper extremity thrombosis and 69 (54.8%) patients with other thrombosis. While 4.5% of patients died during the index episode, 15.4% died within 90 days. Pulmonary embolism was associated with a higher 90-day death risk than lower extremity thrombosis (adjusted hazard ratio 1.23; 95% confidence interval, 1.04-1.47), as was not being discharged on anticoagulants (adjusted hazard ratio 5.56; 95% confidence interval, 4.76-6.67). CONCLUSIONS: In this multicenter, community-based study of patients with acute venous thromboembolism, anticoagulant treatment and outcomes varied by thromboembolism type. Although case fatality during the acute episode was relatively low, 15.4% of people with thromboembolism died within 90 days of the index diagnosis.
BACKGROUND: Few studies describe both inpatient and outpatient treatment and outcomes of patients with acute venous thromboembolism in the United States. METHODS: A multi-institutional cohort of patients diagnosed with confirmed pulmonary embolism or deep venous thrombosis during the years 2004 through 2010 was established from 4 large, US-based integrated health care delivery systems. Computerized databases were accessed and medical records reviewed to collect information on patient demographics, clinical risk factors, initial antithrombotic treatment, and vital status. Multivariable Cox regression models were used to estimate the risk of death at 90 days. RESULTS: The cohort comprised 5497 adults with acute venous thromboembolism. Pulmonary embolism was predominantly managed in the hospital setting (95.0%), while 54.5% of patients with lower extremity thrombosis were treated as outpatients. Anticoagulant treatment differed according to thromboembolism type: 2688 patients (92.8%) with pulmonary embolism and 1625 patients (86.9%) with lower extremity thrombosis were discharged on anticoagulants, compared with 286 patients (80.1%) with upper extremity thrombosis and 69 (54.8%) patients with other thrombosis. While 4.5% of patients died during the index episode, 15.4% died within 90 days. Pulmonary embolism was associated with a higher 90-day death risk than lower extremity thrombosis (adjusted hazard ratio 1.23; 95% confidence interval, 1.04-1.47), as was not being discharged on anticoagulants (adjusted hazard ratio 5.56; 95% confidence interval, 4.76-6.67). CONCLUSIONS: In this multicenter, community-based study of patients with acute venous thromboembolism, anticoagulant treatment and outcomes varied by thromboembolism type. Although case fatality during the acute episode was relatively low, 15.4% of people with thromboembolism died within 90 days of the index diagnosis.
Authors: Charles E Mahan; Matthew E Borrego; Alex L Woersching; Robert Federici; Ross Downey; Jay Tiongson; Mark C Bieniarz; Brendan J Cavanaugh; Alex C Spyropoulos Journal: Thromb Haemost Date: 2012-06-28 Impact factor: 5.249
Authors: Drahomir Aujesky; Pierre-Marie Roy; Franck Verschuren; Marc Righini; Joseph Osterwalder; Michael Egloff; Bertrand Renaud; Peter Verhamme; Roslyn A Stone; Catherine Legall; Olivier Sanchez; Nathan A Pugh; Alfred N'gako; Jacques Cornuz; Olivier Hugli; Hans-Jürg Beer; Arnaud Perrier; Michael J Fine; Donald M Yealy Journal: Lancet Date: 2011-06-22 Impact factor: 79.321
Authors: Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores Journal: Chest Date: 2016-01-07 Impact factor: 9.410
Authors: Karl E Minges; Behnood Bikdeli; Yun Wang; Nancy Kim; Jeptha P Curtis; Mayur M Desai; Harlan M Krumholz Journal: Am J Cardiol Date: 2015-08-14 Impact factor: 2.778
Authors: Christine Baumgartner; Alan S Go; Dongjie Fan; Sue Hee Sung; Daniel M Witt; John R Schmelzer; Marc S Williams; Steven H Yale; Jeffrey J VanWormer; Margaret C Fang Journal: Thromb Res Date: 2020-03-05 Impact factor: 3.944
Authors: Pamela L Lutsey; Rob F Walker; Richard F MacLehose; Faye L Norby; Line H Evensen; Alvaro Alonso; Neil A Zakai Journal: J Am Heart Assoc Date: 2021-10-08 Impact factor: 5.501
Authors: Lauren M Westafer; Meng-Shiou Shieh; Penelope S Pekow; Mihaela S Stefan; Peter K Lindenauer Journal: Acad Emerg Med Date: 2020-12-19 Impact factor: 3.451
Authors: Margaret C Fang; Alan S Go; Priya A Prasad; Jin-Wen Hsu; Dongjie Fan; Cecilia Portugal; Sue Hee Sung; Kristi Reynolds Journal: J Thromb Thrombolysis Date: 2021-04-08 Impact factor: 2.300